This remark notwithstanding, Khorana's book is a very welcome and highly useful volume on the phosphate chemist's shelf and in the chemical and biochemical library, comprehensive within the scope set by the author, and vivid and authoritative as a result of his so eminent involvement in the recent advances of the field under his review.
This small book consists of a series of papers dealing with various aspects of hemodynamics in the macro-circulation of the lungs. The papers have little to say about the micro-circulation or the structure of the vessels themselves. Each paper is followed by a spirited discussion which proves to be a salubrious force against bias. The study group includes some of the most able and experienced investigators in the field. Its members represent an interesting balance between the clinical physiologist and the classical experimental physiologist. Dr. Andre Cournand, in his opening remarks as chairman, emphasizes the great value of the clinical physiologist's observations, then adds, "but it is important that these observations be then, analyzed by the experimental method." The authors present this balance of observation and experimentation, and integrate the data into principles of pulmonary circulation so successfully that the novice reader will gain an understanding in depth as well as breadth with a small expenditure of reading time.
Various methods of assaying the hemodynamic phenomena of the pulmonary circulation are presented and a great deal of cogent discussion centers about the neuro, chemo, and humoral control of the pulmonary circulation. Perhaps the most exciting presentation is that of the group from Postgraduate Medical School who have developed the radioactive oxygen-i5 technique for estimating regional ventilation and perfusion. Although no more important than the other papers for the general field of pulmonary physiology, this is an interesting new technique which represents the conquest of a hitherto unsolved problem. This is a report of a symposium on the methodology of evalution of drug therapy in neurological disease. It was held at the University of Wisconsin and was supported by a grant from the U.S.P.H.S. The role of the pharmacologist, the pharmaceutical industry and the Food and Drug Administration is presented in the first section, that of the biostatistician in planning controlled clinical trials in the second, and reports of he panels on various disease entities in the last.
The participants in the first section discuss the value and the limitations of animal screening and the ultimate importance of controlled clinical I54
